ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.

被引：0
|
作者：
Olawaiye, Alexander
Monk, Bradley J.
Herzog, Thomas J.
Copeland, Larry J.
Coleman, Robert L.
Moore, Kathleen N.
Randall, Leslie M.
Slomovitz, Brian M.
O'Malley, David M.
Eskander, Ramez Nassef
Pothuri, Bhavana
Van Gorp, Toon
Pignata, Sandro
Nicum, Shibani
Tudor, Iulia Cristina
Nguyen, Dorothy D.
Lorusso, Domenica
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Creighton Univ Sch Med, Univ Arizona Coll Med, GOG Fdn, Phoenix, AZ USA
[3] Univ Cincinnati Canc Inst, Cincinnati, OH USA
[4] Ohio State Univ, James Canc Ctr, Columbus, OH USA
[5] US Oncol Res, Spring, TX USA
[6] Univ Oklahoma HSC, Stephenson Canc Ctr, Oklahoma City, OK USA
[7] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[8] Florida Int Univ, Mt Sinai Med Ctr, Miami Beach, FL USA
[9] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA
[10] Moores Canc Ctr, La Jolla, CA USA
[11] NYU Grossman Sch Med, Perlmutter Canc Ctr, NYU Langone Hlth, Ney York, NY USA
[12] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[13] Ist Nazl Tumori Napoli, Naples, Italy
[14] Univ Coll London Canc Inst, London, England
[15] Corcept Therapeut, Menlo Pk, CA USA
[16] Catholic Univ, IRCCS, Sacred Heart & Fondazione Policlinico Gemelli, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5620
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ARTISTRY-7: PHASE 3 MULTICENTER STUDY OF NEMVALEUKIN ALFA PLUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Herzog, Thomas
    Hays, John
    Moore, Kathleen
    Konstantinopoulos, Panagiotis
    Gilbert, Lucy
    Monk, Bradley
    O'Malley, David
    Barlin, Joyce
    Rege, Jessicca
    Desai, Monali
    Du, Yangchun
    Dalal, Rita
    Coleman, Robert L.
    Sehouli, Jalid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
  • [22] Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Ray-Coquard, Isabelle
    Braicu, Ioana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Zeimet, Alain G.
    lauraine, Eric Pujade
    Cassier, Philippe Alexandre
    Moll, Utemartha
    Ulmer, Hanno
    Leunen, Karin
    Marth, Christian
    Vergote, Ignace
    Concin, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial
    Coleman, Robert L.
    Handley, Katelyn F.
    Burger, Robert
    Dal Molin, Graziela Zibetti
    Stagg, Robert
    Sood, Anil K.
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 386 - 391
  • [24] A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Moore, K. N.
    Cadoo, K. A.
    Chambers, S.
    Ghamande, S.
    Konecny, G.
    Oza, A. M.
    Chen, L-M.
    Konstantinopoulos, P. A.
    Lea, J.
    Spitz, D.
    Uyar, D.
    Mugundu, G.
    Laing, N.
    Strickland, D. K.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
    Moore, Kathleen N.
    Angelergues, Antoine
    Konecny, Gottfried E.
    Banerjee, Susana N.
    Pignata, Sandro
    Colombo, Nicoletta
    Moroney, John William
    Cosgrove, Casey
    Lee, Jung-Yun
    Roszak, Andrzej
    Breuer, Shani
    Tromp, Jacqueline Maria
    Bello-Roufai, Diana
    Gilbert, Lucy
    Miller, Rowan
    Myers, Tashanna K. N.
    Wang, Yuemei
    Berkenblit, Anna
    Lorusso, Domenica
    Van Gorp, Toon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA5507 - LBA5507
  • [26] ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Herzog, Thomas
    Moore, Kathleen
    Konstantinopoulos, Panagiotis
    Gilbert, Lucy
    Hays, John
    Monk, Bradley
    O'Malley, David
    Sehouli, Jalid
    Graham, Julie
    Desai, Monali
    Wang, Yan
    Du, Yangchun
    Sun, Lei
    Dalal, Rita
    Coleman, Robert
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S169 - S169
  • [27] Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
    Moore, Kathleen N.
    Angelergues, Antoine
    Konecny, Gottfried E.
    Banerjee, Susana N.
    Pignata, Sandro
    Colombo, Nicoletta
    Moroney, John William
    Cosgrove, Casey
    Lee, Jung-Yun
    Roszak, Andrzej
    Breuer, Shani
    Tromp, Jacqueline Maria
    Bello-Roufai, Diana
    Gilbert, Lucy
    Miller, Rowan
    Myers, Tashanna K. N.
    Wang, Yuemei
    Berkenblit, Anna
    Lorusso, Domenica
    Van Gorp, Toon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [28] Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Concin, Nicole
    Braicu, Loana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Zeimet, Alain G.
    Pujade-Lauraine, Eric
    Cassier, Philippe Alexandre
    Moll, Ute Martha
    Ulmer, Hanno
    Leunen, Karin
    Marth, Christian
    Vergote, Ignace
    Ray-Coquard, Isabelle Laure
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
    Fu, S.
    Burger, R. A.
    Hamilton, E.
    Corr, B. R.
    Naumann, R. W.
    Wenham, R. M.
    Morgan, M. A.
    Stagg, R.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 14 - 15
  • [30] A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC)
    McNeish, Iain A.
    Ledermann, Jonathan A.
    Webber, Lee C.
    James, Lindsay E.
    Kaye, Stanley B.
    Rustin, Gordon J. S.
    Hall, Geoff
    Clamp, Andrew
    Earl, Helena Margaret
    Banerjee, Susana N.
    Kristeleit, Rebecca Sophie
    Raja, Fharat
    Feeney, Amanda
    Lawrence, Cheryl
    Dawson-Athey, Linda
    Persic, Mojca
    Khan, Iftekhar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345